Clinical Trials Logo

Light Chain (AL) Amyloidosis clinical trials

View clinical trials related to Light Chain (AL) Amyloidosis.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05692908 Withdrawn - Clinical trials for Light Chain (AL) Amyloidosis

An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis

Start date: September 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1 open-label, dose escalation trial designed to identify the recommended phase 2 dose of STI-6129 by assessing the safety, preliminary efficacy, and immunogenicity in subjects with relapsed or refractory systemic AL Amyloidosis

NCT ID: NCT04943302 Withdrawn - Amyloidosis Clinical Trials

Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis

Start date: September 2022
Phase: Phase 2
Study type: Interventional

Patients with systemic light chain (AL) amyloidosis, particularly those who are ineligible for transplant or have relapsed/refractory disease, have limited treatment options. The combination of bendamustine and dexamethasone is well-tolerated and efficacious in patients with relapsed/refractory AL amyloidosis. Anti-CD38 antibodies have recently demonstrated great efficacy in AL amyloidosis. Adding isatuximab, a monoclonal antibody targeting CD38, to bendamustine would combine two mechanisms of targeting the clonal plasma cell without significant overlap in toxicity. This would provide a steroid minimizing and neurotoxic-free regimen for patients with AL amyloidosis. This study is a phase II clinical trial of isatuximab and bendamustine in newly diagnosed or relapsed/refractory AL amyloidosis. It is hypothesized that this combination will result in a high number of deep hematologic responses.